Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

ADENOCARD LIQ IV 3MG/ML 3 MG

ADENOSINE : 3 MG · DIN 02030306 · FUJISAWA PHARMACEUTICAL CO, DIVISION OF FUJISAWA CANADA INC.

Health Canada status: CANCELLED POST MARKET

What is ADENOCARD LIQ IV 3MG/ML?

ADENOCARD LIQ IV 3MG/ML 3 MG contains ADENOSINE : 3 MG. It is listed in the Health Canada Drug Product Database under DIN 02030306, held by FUJISAWA PHARMACEUTICAL CO, DIVISION OF FUJISAWA CANADA INC., supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 09-Sep-1996. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

Product details and regulatory record

DIN02030306
Brand nameADENOCARD LIQ IV 3MG/ML
Generic / active ingredientADENOSINE : 3 MG
ManufacturerFUJISAWA PHARMACEUTICAL CO, DIVISION OF FUJISAWA CANADA INC.
Strength3 MG
Dosage formLIQUID
Route of administrationINTRAVENOUS
SchedulePrescription
ATC codeC01EB10 ADENOSINE
AHFS class24:04.92
BiosimilarNo
Health Canada statusCANCELLED POST MARKET
Status date09-Sep-1996
Original market date1993-12-31 00:00:00

What can be used instead?

Other Canadian products sharing ATC code C01EB10 ADENOSINE. 3 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
ADENOSINE INJECTION3 MGSOLUTIONFRESENIUS KABI CANADA LTDMARKETEDDIN 02267659
ADENOSINE INJECTION3 MGSOLUTIONFRESENIUS KABI CANADA LTDMARKETEDDIN 02457482
ADENOSINE INJECTION3 MGSOLUTIONFRESENIUS KABI CANADA LTDMARKETEDDIN 02457474
ADENOCARD - LIQ RAPID BOLUS IV 3MG/ML3 MGSOLUTIONASTELLAS PHARMA CANADA INCCANCELLED POST MARKETDIN 02139308
ADENOCARD INJECTION -PRE-FILLED SYRINGE3 MGSOLUTIONASTELLAS PHARMA CANADA INCCANCELLED POST MARKETDIN 02145820
ADENOCARD LIQ IV 3MG/ML (PRE-FILLED SYRINGE)3 MGLIQUIDFUJISAWA PHARMACEUTICAL CO, DIVISION OF FUJISAWA CANADA INC.CANCELLED POST MARKETDIN 02031078
ADENOSCAN - (FOR IV INFUSION ONLY)3 MGSOLUTIONASTELLAS PHARMA CANADA INCCANCELLED POST MARKETDIN 02139294
ADENOSINE INJECTION, USP3 MGSOLUTIONMYLAN PHARMACEUTICALS ULCCANCELLED PRE MARKETDIN 02401061
ADENOSINE INJECTION, USP3 MGSOLUTIONMYLAN PHARMACEUTICALS ULCCANCELLED PRE MARKETDIN 02409585
AJ-ADENOSINE3 MGSOLUTIONAGILA JAMP CANADA INCCANCELLED PRE MARKETDIN 02402246

Who else supplies ADENOSINE worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. ADENOSINE appears in 38 registered pack listings across 7 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for ADENOCARD LIQ IV 3MG/ML

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for ADENOCARD LIQ IV 3MG/ML

Health Canada Drug Product Database (DPD), DIN 02030306. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.